US OptionsDetailed Quotes
ARQT250516P12500
- 0.30
- -0.05-14.29%
15min DelayClose Apr 30 15:59 ET
0.65High0.30Low
0.65Open0.35Pre Close9 Volume133 Open Interest12.50Strike Price318.00Turnover99.66%IV18.18%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type-0.1667Delta0.0814Gamma49.70Leverage Ratio-0.0244Theta-0.0011Rho-8.28Eff Leverage0.0077Vega
Arcutis Biotherapeutics Stock Discussion
Arcutis Biotherapeutics
(ARQT.US)
Tonix Pharmaceuticals
(TNXP.US)
As of March 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price act...
Could This New Eczema Cream Bring Relief to Millions of Toddlers? FDA Now Reviewing
📊⚡️📊
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
Positive
▪️Q4 2024 revenue grew 366% YoY to $63 million
▪️Full-year 2024 revenue increased 449% YoY to $160 million
▪️Strong quarter-over-quarter growth of 41% in Q4 2024
▪️Robust liquidity position of $329 million including available debt
▪️Option to re-draw $100 million deb...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...
Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rubric Capital Management LP(9.38%),David Rosen(9.38%)
Long-term! 😜
1 MINUTE AGO, 8:20 AM EDT
VIA GLOBENEWSWIRE
No comment yet